Literature DB >> 882156

Canrenoate disposition in dogs. Tissue distribution and elimination.

J Kuhlmann, V Kötter, N Rietbrock.   

Abstract

The metabolism and tissue distribution of intravenously administered C14-canrenoate-potassium (CR-K) was studied at various time intervals in 10 dogs. After a rapid decline of total radioactivity immediately after injection, the elimination in plasma occurred in two distinct phases with half-lives of 6.8 and 23.6 h. Canrenoate was rapidly converted to lipid- and water-soluble metabolites which were separated by thin-layer chromatography. Most tissues showed similar concentrations of total radioactivity as plasma. An accumulation of radioactivity per g wet weight was detected in the adrenal glands and fat tissue as well as in the metabolic and excretory organs but not in the heart. Taking into consideration that skeletal muscle, fat tissue and liver constitute about 64% of the body weight, it is obvious that the main part of total radioactivity was present in these tissues. In contrast to plasma, urine and feces, where various metabolites could be analysed, the bulk of radioactivity in tissues is represented by canrenone. Thus, the estimation of the parent compound and its metabolites in plasma, urine and feces does not allow final conclusions about the active substance in various tissues. Within 72 h 47% of the dose was recovered in urine and 49% in feces.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 882156     DOI: 10.1007/bf00508627

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  32 in total

Review 1.  [ALDOSTERONE AND ALDOSTERONISM. NEW RESULTS AND EXPERIENCES].

Authors:  H P WOLFF
Journal:  Klin Wochenschr       Date:  1964-08-01

2.  Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone.

Authors:  C M KAGAWA
Journal:  Endocrinology       Date:  1960-07       Impact factor: 4.736

3.  Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.

Authors:  A Karim; J Hribar; W Aksamit; M Doherty; L J Chinn
Journal:  Drug Metab Dispos       Date:  1975 Nov-Dec       Impact factor: 3.922

4.  Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of a case.

Authors:  J A Sundsfjord; P Marton; H Jorgensen; A Aakvaag
Journal:  J Clin Endocrinol Metab       Date:  1974-10       Impact factor: 5.958

5.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

6.  Use of potassium canrenoate to suppress ouabain-induced ventricular arrhythmias in dogs.

Authors:  B K Yeh; P K Sung; A K Saha
Journal:  Circ Res       Date:  1972-12       Impact factor: 17.367

7.  Prediction of stability in pharmaceutical preparations. XVI. Kinetics of hydrolysis of canrenone and lactonization of canrenoic acid.

Authors:  E R Garrett; C M Won
Journal:  J Pharm Sci       Date:  1971-12       Impact factor: 3.534

8.  Prevention of digitoxin poisoning by various steroids.

Authors:  H Selye; J Jelinek; M Krajny
Journal:  J Pharm Sci       Date:  1969-09       Impact factor: 3.534

9.  Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine.

Authors:  K Koch; M Senn; W Steingross
Journal:  Steroids       Date:  1976-10       Impact factor: 2.668

10.  Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).

Authors:  A Karim; E A Brown
Journal:  Steroids       Date:  1972-07       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.